Recent advances in asthma therapy have included several new biologic agents that modify Th2-inflammatory pathways. Treatment guidelines have provided a framework for the treatment of patients with Th2-mediated allergic asthma. However, approximately half of asthmatic patients do not fall within the Th2 inflammatory paradigm. Cinicians must be knowledgeable of treatment options and the role of potential novel therapies for this subgroup of patients.